Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 1
1985 2
1986 3
1987 1
1988 4
1989 4
1990 4
1991 5
1992 5
1993 4
1994 2
1995 2
1996 3
1997 4
1998 3
1999 1
2000 3
2003 2
2004 1
2005 2
2007 2
2008 1
2009 1
2010 1
2012 2
2013 2
2014 4
2015 2
2016 4
2017 2
2018 5
2019 5
2020 3
2021 4
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for petruzzelli s
Search for Petruzzeli S instead (1 results)
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Papi A, et al. Among authors: petruzzelli s. Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Lancet. 2018. PMID: 29429593 Clinical Trial.
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Virchow JC, et al. Among authors: petruzzelli s. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. Lancet. 2019. PMID: 31582314 Clinical Trial.
Asthma progression and mortality: the role of inhaled corticosteroids.
O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. O'Byrne P, et al. Among authors: petruzzelli s. Eur Respir J. 2019 Jul 18;54(1):1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Eur Respir J. 2019. PMID: 31048346 Free PMC article. Review.
Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease.
Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, Pasquale CB, Merrill DD, Metzdorf N, Petruzzelli S, Tal-Singer R, Compton C, Rennard S, Martin UJ. Singh D, et al. Among authors: petruzzelli s. Am J Respir Crit Care Med. 2020 Sep 1;202(5):660-671. doi: 10.1164/rccm.201912-2384PP. Am J Respir Crit Care Med. 2020. PMID: 32186896 Free PMC article. Review. No abstract available.
Objectively Measured Physical Activity as a COPD Clinical Trial Outcome.
Burtin C, Mohan D, Troosters T, Watz H, Hopkinson NS, Garcia-Aymerich J, Moy ML, Vogiatzis I, Rossiter HB, Singh S, Merrill DD, Hamilton A, Rennard SI, Fageras M, Petruzzelli S, Tal-Singer R, Tomaszewski E, Corriol-Rohou S, Rochester CL, Sciurba FC, Casaburi R, Man WD, Van Lummel RC, Cooper CB, Demeyer H, Spruit MA, Vaes A; CBQC Task Force on Physical Activity. Burtin C, et al. Among authors: petruzzelli s. Chest. 2021 Dec;160(6):2080-2100. doi: 10.1016/j.chest.2021.06.044. Epub 2021 Jul 1. Chest. 2021. PMID: 34217679 Review.
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Vanfleteren L, et al. Among authors: petruzzelli s. Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30587953 Free PMC article. Review.
The role of suspicion in the diagnosis of pulmonary embolism.
Palla A, Petruzzelli S, Donnamaria V, Giuntini C. Palla A, et al. Among authors: petruzzelli s. Chest. 1995 Jan;107(1 Suppl):21S-24S. doi: 10.1378/chest.107.1_supplement.21s. Chest. 1995. PMID: 7813324 Review.
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammat… See abstract for full author list ➔ Izadi Z, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639. JAMA Netw Open. 2021. PMID: 34661663 Free PMC article.
100 results